Nextrials and InClin Partner on Integrated Clinical Research Services

Nextrials, Inc.

, a provider of clinical research software and services, announced a partnership with

InClin

, a specialized clinical research organization (CRO) conducting Phase 1-4 studies for the pharmaceutical, biotechnology and medical device industries. With this partnership, researchers can take full advantage of each company’s strengths by linking Nextrials’

Prism

®, an award winning clinical trial data management platform, with InClin’s personalized, high-quality services to accelerate study starts and significantly lower drug development costs.

“Our companies have similar approaches to research, particularly when it comes to offering exceptional clinical trial performance and service,” said Dirk Thye, MD, CEO of InClin. “We take pride in our ability to deliver superior data quality to our sponsors, and Nextrials’ Prism meets our high standards as an enabling data management platform that can significantly shorten the length of time it takes to initiate and monitor a clinical trial. Together, we can help sponsors attain high quality data and potentially expedite the path to approval.”

Prism, its design tools and its new iPad interface give pharmaceutical and biotech researchers anytime/anywhere access to key data points, reports and statistics about ongoing studies, regardless of location. It enables sponsors to better manage investigator site data, logistics and costs, including access to real-time data related to patient demographics, recruitment/enrollment status, queries and more.

“As clinical trials become more complex, partnerships such as this one remove some of the organizational and integration headaches from study initiation and monitoring,” said James Rogers, CEO and co-founder of Nextrials. “Prism’s capabilities, combined with InClin’s senior project management team and its standardized performance indicators and quality metrics processes, give sponsors an edge in obtaining critical study data on a timely basis and keeping studies on track.”